A.-É. Heng

Immunomodulatory properties of mesenchymal stromal cells

A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients – the HEALTHY-CATH trial

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation

PharmGKB summary

TFOS DEWS II Management and Therapy Report

A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor–Based Immunosuppression? A Systematic Review and Meta-Analysis

Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients

Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production

Immune modulation by mesenchymal stem cells

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

An Ethanol/Sodium Citrate Locking Solution Compared to Heparin to Prevent Hemodialysis Catheter-Related Infections: a Randomized Pilot Study

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Effect of a New FunctionalCYP3A4Polymorphism on Calcineurin Inhibitors‘ Dose Requirements and Trough Blood Levels in Stable Renal Transplant Patients

Practical Recommendations for Pharmacogenomics-based Prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics

Role for CD4+CD25+ T Cells in Inhibition of Graft Rejection by Extracorporeal Photopheresis

Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults

Using Genetic and Clinical Factors to Predict Tacrolimus Dose in Renal Transplant Recipients

KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

Impact of short term use of interdialytic 60% ethanol lock solution on tunneled silicone catheter dysfunction

PUVA apoptotic response in activated and resting human lymphocytes

Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment